Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was up 4.5% on Thursday . The company traded as high as $7.06 and last traded at $7.00, with a volume of 61,482 shares trading hands. The stock had previously closed at $6.70.

A number of equities research analysts recently weighed in on KPTI shares. Wedbush reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, August 4th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Robert W. Baird started coverage on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. They issued an “outperform” rating and a $16.00 target price on the stock. Raymond James Financial Inc. initiated coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price on the stock. Finally, Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday, June 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $19.50.

The stock’s market cap is $250.12 million. The stock has a 50-day moving average of $7.18 and a 200 day moving average of $7.78.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.08. On average, equities analysts forecast that Karyopharm Therapeutics Inc. will post ($3.27) EPS for the current fiscal year.

In related news, major shareholder Ltd Chione sold 63,800 shares of the business’s stock in a transaction that occurred on Wednesday, May 18th. The stock was sold at an average price of $8.15, for a total value of $519,970.00. Following the transaction, the insider now directly owns 8,923,932 shares of the company’s stock, valued at approximately $72,730,045.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned about 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent filing with the SEC.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.